ANI Pharmaceuticals, Inc. (ANIP)

Over the past six months, ANI Pharmaceuticals' stock price has seen significant movement, increasing by 24.48% and showing a 52.83% increase between December 23, 2024, and December 19, 2025. The company announced strong preliminary unaudited results for 2025 and provided an upbeat financial forecast for 2026, projecting total net revenues between $1.055 billion and $1.115 billion, initially causing the stock to rally more than 10%. Following the positive guidance, the stock experienced a subsequent drop of 3.3% as investors engaged in profit-taking. Zacks Research downgraded ANI Pharmaceuticals from a "strong-buy" to a "hold" rating on January 8, 2026, although the overall analyst consensus remained a "Moderate Buy." ANI Pharmaceuticals reported impressive financial results for the third quarter of 2025, with an EPS of $2.04, surpassing expectations, and revenue of $227.8 million, exceeding forecasts. The acquisition of Alimera Sciences in 2024 expanded the Rare Disease portfolio, adding ophthalmology assets ILUVIEN and YUTIQ, which diversified revenue streams and increased 2025 guidance.

ANI Pharmaceuticals' management has indicated that recent gains in revenue reflect underlying demand rather than seasonality or one-time benefits, suggesting that there is no significant demand seasonality for ANI Pharmaceuticals' products and services.

ANI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals, as well as over-the-counter medicines and treatments for rare diseases, and operates as a contract development and manufacturing organization. ANI Pharmaceuticals operates within the Healthcare sector, specifically in the Biotechnology and Specialty & Generic Drug Manufacturers industries, with a business model divided into three core segments: Rare Disease, Generics, and Established Brands. The company's Rare Disease products include Purified Cortrophin Gel, ILUVIEN, and YUTIQ. The Generics portfolio includes Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone, Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema, and Vancomycin, specializing in controlled substances, oncolytics, hormones, steroids, and complex formulations. The Established Brands segment includes a portfolio of over 16 brand products. Recently approved NDAs include INZIRQO and TEZRULY. The company produces oral solid dose products, liquids, topicals, narcotics, potent products, injectables, and softgel capsules.

ANI Pharmaceuticals primarily conducts its operations and generates the majority of its revenue in the United States and also has a market presence in Canada.

ANI Pharmaceuticals has generally maintained a positive brand reputation, driven by strong financial performance and strategic growth, particularly within its Rare Disease segment. The company's successful relaunch of Purified Cortrophin Gel and the acquisition of Alimera Sciences have been highlighted as key drivers of revenue growth and market expansion. Management's emphasis on addressing unmet medical needs and providing access to critical medicines also contributes positively to its reputation. While a recent downgrade by Zacks Research from "strong-buy" to "hold" occurred, the overall analyst consensus remains a "Moderate Buy," suggesting a generally favorable view.

ANI Pharmaceuticals' ownership structure is largely concentrated among institutional investors, who hold a significant majority of the company's stock, ranging from approximately 61.14% to 91.45%. Insiders hold about 8.43% of the stock, while public companies and individual investors own between 19.99% and 30.43%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, IJR - iShares Core S&P Small-Cap ETF, State Street Corp, Global Alpha Capital Management Ltd., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, UBS Group AG, Citadel Advisors Llc, Dimensional Fund Advisors Lp, and Geode Capital Management, Llc.